Status:

UNKNOWN

Theta Burst Stimulation for Headaches After Traumatic Brain Injury

Lead Sponsor:

Minneapolis Veterans Affairs Medical Center

Collaborating Sponsors:

Minnesota Office of Higher Education

The Defense and Veterans Brain Injury Center

Conditions:

Post-Traumatic Headache

Transcranial Magnetic Stimulation

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

The purpose of this study is to evaluate if theta burst stimulation (TBS) can reduce chronic headaches caused by a traumatic brain injury (TBI). TBS is a safe, drug-free brain stimulation technique th...

Detailed Description

The primary objective of this study is to investigate the safety and efficacy of theta burst stimulation (TBS) for the management of post-traumatic headaches to improve outcomes and quality of life fo...

Eligibility Criteria

Inclusion

  • Veterans receiving services through the MVAHCS
  • History of mild TBI according to VA/DoD Clinical Practice Guidelines (2009) with one or more of the following criteria present after head injury:
  • Loss of consciousness between 0-30 minutes
  • Post-traumatic amnesia between 0-24 hours
  • Alteration of consciousness/mental state up to 24 hours
  • Glasgow Coma Score between 13-15 (best available score within first 24 hours)
  • Post-traumatic headaches defined by International Classification for Headache Diagnosis 3rd Edition (ICHD-3) guidelines with the following criteria present:
  • Headaches developing within seven days following trauma or injury to the head and/or neck
  • Headaches persisting beyond three months
  • Chronic daily headaches defined by clinical standards with the following criterion present:
  • o 15 or more headache days per month
  • Men and women 18-75 years of age
  • Possess a smartphone and agree to download and use the EMA application on their personal device
  • Capable and willing to provide voluntary informed consent

Exclusion

  • History of moderate or severe TBI according to VA/DoD Clinical Practice Guidelines (2009) with one or more of the following criteria present after head injury:
  • Loss of consciousness greater than 30 minutes
  • Post-traumatic amnesia greater than 24 hours
  • Worst Glasgow Coma Scale less than 13 within the first 24 hours unless invalidated upon review (e.g., attributable to intoxication, sedation, systemic shock)
  • Abnormal structural imaging
  • Current (within six months of enrollment) psychosis and mania
  • Current (within one month of enrollment) substance dependence with the exclusion of opioids
  • Personal history of epilepsy or seizure disorder
  • o Does not include seizures therapeutically-induced by ECT or identified as a single seizure event (based on the principal investigator's judgement)
  • Metal particles in the eye or head (exclusive of the mouth) (e.g., shrapnel, fragments from welding or metalwork, etc.)
  • Implanted medical device above the clavicle (e.g., aneurysm clips, shunts, stimulators, cochlear implants, electrodes, etc.)
  • Significant neurological disorder or insult that would impact risk (based on the principal investigator's judgement and research literature)
  • Current use of medications with significant potential for lowering seizure threshold
  • Current benzodiazepine usage at a dose higher than 3mg of lorazepam or equivalent
  • Electroconvulsive therapy (ECT) or cortical energy exposure within one month of enrollment (including participation in any other neuromodulation treatments or studies)
  • Current (within one month of enrollment) participation in another interventional study that would impact the results of this research
  • Inadequate communication (e.g., language barrier)
  • Women who are pregnant, trying to become pregnant, or breastfeeding
  • Women of childbearing age/potential who are not using a medically-accepted form of contraception when sexually active

Key Trial Info

Start Date :

November 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2023

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT04906603

Start Date

November 1 2019

End Date

September 1 2023

Last Update

May 28 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Minneapolis VA Health Care System

Minneapolis, Minnesota, United States, 55417